AI firm Anthropic has been actively making strides in the biopharmaceutical landscape lately. It has not only appointed a corporate development lead with a specialized focus on biopharmaceuticals but also launched the '100-Day Blitz' campaign from April through to the end of June. Throughout this campaign, Anthropic acquired Coefficient Bio for $400 million and onboarded top-tier talent, including the ex-CEO of Novartis and a co-creator of AlphaFold. Moreover, Anthropic unveiled Claude for Sciences, a vertical solution designed specifically for the pharmaceutical industry, and disclosed its plans to develop its own preclinical-stage drugs targeting neglected diseases, while also expanding its team with positions related to wet lab experiments. Industry experts are of the opinion that Anthropic harbors significant ambitions for transactions within the biotechnology sector and might commence IPO roadshows as soon as next month, with a valuation that could soar to $2 trillion.

At present, leading AI companies are increasingly making forays into the biopharmaceutical realm. An entrepreneur-in-residence at Cambridge Innovation Capital highlighted that this sector has the potential to generate entirely novel economic value, thereby justifying the high valuations of AI companies. Presently, AI companies operating in the biopharmaceutical sector predominantly adopt one of two strategies: one is to position themselves as tool or infrastructure providers, akin to OpenAI and NVIDIA; the other is to commence with fundamental scientific research, progress AI-driven drug development pipelines, and collaborate with pharmaceutical firms, as exemplified by Google's Isomorphic Labs.

Anthropic, however, has embraced a strategy that straddles these two approaches. It not only furnishes tools to pharmaceutical companies but also establishes its own labs and cultivates its own drug pipelines, thereby assuming a dual role as both a service provider and a competitor. This strategy has elicited mixed reactions from pharmaceutical companies. While they are keen to harness AI to bolster efficiency, they are equally apprehensive about the security of their core data. Anthropic's strategic moves have ignited in-depth industry discussions on issues such as the degree to which AI companies can infiltrate the pharmaceutical value chain and how pharmaceutical companies can strike a balance between efficiency and risk.